ABOUT THE MOLECULE
Claris is pioneering new innovations for a significant patient population struggling with the impacts of corneal scarring.
Hepatocyte growth factor (HGF) is a cytokine that stimulates epithelial cell proliferation, movement, structure, and the formation of blood vessels in several tissues throughout the body, including the cornea.17 Across these tissues, HGF is secreted by stromal and mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on T cells.18 HGF is a growth factor known to:
- Accelerate wound healing and reduce inflammation
- Reduce and reverse scarring
- Support the growth of nerves
Additionally, the anti-fibrotic and healing properties seen with HGF has been demonstrated across many disease models and medical conditions.
Claris has identified that a deletion variant of hepatocyte growth factor (dHGF), in which five amino-acid residues are deleted, can accelerate corneal wound healing and prevent and reverse corneal scarring. dHGF has the potential to support restoration of both structural and functional corneal integrity resulting from disease, mechanical or chemical injury, and infection.
Initially named “Scatter Factor,” dHGF contains altered solubility and immunological properties while retaining the biological activities of the full sized protein.19
Claris is developing a human recombinant dHGF, CSB-001, for the treatment of NK and is administered topically as a 0.1% ophthalmic solution. The unique mechanism of action has demonstrated greater activity than a comparator molecule in the treatment of neurotrophic keratitis.
CSB-001 is a heterodimeric molecule consisting of a 69-kD α-chain and 34-kD β-chain that binds to c-MET, a receptor tyrosine kinase involved in wound healing that is unregulated in corneal disease.20,21
CSB-001 is stored at room temperature, dosed (1 drop) four times daily, and administered via an easy to handle sterile droptainer dispenser.